Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy

David A. Tessa Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Cambridge, MA, USAView further author information

Tristan S. Maurera Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Cambridge, MA, USAView further author information

Zhenhong Lia Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Cambridge, MA, USAView further author information

Christine Bulawab Rare Disease Research Unit, Pfizer Inc., Cambridge, MA, USAView further author information

James Flemingb Rare Disease Research Unit, Pfizer Inc., Cambridge, MA, USAView further author information

Amy T. Moodya Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Cambridge, MA, USACorrespondence[email protected]
View further author information

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.